Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences.... Oct 31
Everest Medicines today announced a strategic equity investment in I-Mab, under which Everest will invest US$30.9 million in cash.... Aug 05
I-Mab's global collaboration with AbbVie will facilitate global development of lemzoparlimab... Dec 05
AbbVie and I-Mab enter Into global strategic partnership for differentiated immuno-oncology therapy ... Sep 04
-Advertisements-